WEBER , Jeffrey

Last name: WEBER

First name: Jeffrey

March 5, 2024 (v1)

Publication

Metadata-only

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

Larkin, James Weber, Jeffrey Del Vecchio, Michele

Abstract Purpose: Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisions for patients...

Uploaded on: March 7, 2024
September 30, 2022 (v1)

Publication

Metadata-only

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Mandala, Mario Larkin, James R. Ascierto, Paolo Antonio

Background Several therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding of their benefit‒risk profiles in order to make informed treatment decisions. Herein we characterize adjuvant nivolumab select (immune-related) treatment-related adverse events (TRAEs) and evaluate possible associations...

Uploaded on: March 24, 2023
February 29, 2024 (v1)

Publication

Metadata-only

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Larkin, James Del Vecchio, Michele Mandalá, Mario

lumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IVmelanoma,with benefit sustained at 4 years. We report updated 5-year efficacy and biomarker findings. Patients and Methods: Patients with resected stage IIIB–C/IV melanoma were...

Uploaded on: March 3, 2024

WEBER , Jeffrey

Recent uploads